(%)
| 2020/3 | 2021/3 | 2022/3 | 2023/3 | 2024/3 | ||
|---|---|---|---|---|---|---|
| Return of Equity (ROE) | Full year | 4.3 | -3.6 | 3.3 | 5.9 | 4.5 |
(%)
| 2021/3 | 2022/3 | 2023/3 | 2024/3 | 2025/3 | ||
|---|---|---|---|---|---|---|
| Equity ratio* | Full year | 48.7 | 48.7 | 43.3 | 45.4 | - |
| Q4 | 48.7 | 48.7 | 43.3 | 45.4 | - | |
| Q3 | 48.6 | 48.3 | 43.4 | 44.7 | - | |
| Q2 | 48.8 | 48.8 | 44.5 | 45.4 | - | |
| Q1 | 49.2 | 49.0 | 48.3 | 44.5 | 46.0 | |
(Yen)
| 2020/3 | 2021/3 | 2022/3 | 2023/3 | 2024/3 | ||
|---|---|---|---|---|---|---|
| Earnings per share(EPS):Basic | Full year | 54.58 | -45.20 | 45.35 | 88.13 | 72.58 |
| Dividends per share | Full year | 26.00 | 15.00 | 26.00 | 34.00 | 36.00 |
(%)
| 2020/3 | 2021/3 | 2022/3 | 2023/3 | 2024/3 | ||
|---|---|---|---|---|---|---|
| Dividend payout ratio | Full year | 47.6 | - | 57.3 | 38.6 | 49.6 |
(Million yen)
| 2020/3 | 2021/3 | 2022/3 | 2023/3 | 2024/3 | ||
|---|---|---|---|---|---|---|
| R&D Expenditure | Full year | 102,851 | 90,387 | 96,721 | 107,748 | 109,898 |
| R&D expenditures/Total sales | Full year | 5.1 | 5.4 | 5.5 | 5.0 | 4.7 |
(Million yen)
| 2020/3 | 2021/3 | 2022/3 | 2023/3 | 2024/3 | ||
|---|---|---|---|---|---|---|
| Capital Investments | Full year | 86,596 | 42,155 | 37,359 | 45,458 | 53,267 |
| Depreciation for tangible fixed assets | Full year | 62,528 | 45,389 | 39,851 | 41,995 | 44,020 |